Application and performance of disease activity indices proposed for patients with systemic sclerosis in an international cohort of patients with juvenile systemic sclerosis

Jens Klotsche*, Kathryn S Torok, Ozgur Kasapcopur, Amra Adrovic, Maria Teresa Terreri, Ana Paula Sakamoto, Maria Katsicas, Flavio Sztajnbok, Edoardo Marrani, Alberto Sifuentes-Giraldo, Valda Stanevicha, Jordi Anton, Brian Feldmann, Mikhail Kostik, Dana Nemcova, Maria Jose Santos, Simone Appenzeller, Tadej Avcin, Cristina Battagliotti, Lillemor BerntsonBlanca Bica, Jürgen Brunner, Despina Eleftheriou, Liora Harel, Gerd Horneff, Tilmann Kallinich, Kirsten Minden, Susan Nielsen, Anjali Patwardhan, Nicola Helmus, Ivan Foeldvari

*Corresponding author af dette arbejde

Abstract

OBJECTIVES: Juvenile systemic sclerosis is a rare childhood disease. Three disease activity indices have been published for adult patients with systemic sclerosis: the European Scleroderma Study Group Index, a modified version of the European Scleroderma Study Group Index and the revised European Scleroderma Trials and Research index. The objective of this study was to determine the feasibility and performance of the three disease activity indices in a prospectively followed cohort of patients with juvenile systemic sclerosis.

METHODS: The analysis cohort was selected from the prospective international inception cohort enrolling juvenile systemic sclerosis patients. The correlation of the disease activity indices with the physicians' and the patients' global assessment of disease activity was determined. The disease activity indices were compared between patients with active and inactive disease. Sensitivity to change between 6- and 12-month follow-up was investigated by mixed models.

RESULTS: Eighty percent of the 70 patients had a diffuse cutaneous subtype. The revised European Scleroderma Trials and Research index was highly correlated with the physician-reported global disease activity/parents-reported global disease activity (r = 0.74/0.64), followed by the European Scleroderma Study Group activity index (r = 0.61/0.55) and the modified version of the European Scleroderma Study Group activity index (r = 0.51/0.43). The disease activity indices significantly differed between active and inactive patients. The disease activity indices showed sensitivity to change between 6- and 12-month follow-up among patients who improved or worsened according to the physician-reported global disease activity and the parents-reported global disease activity.

CONCLUSION: Overall, no disease activity score is superior to the other, and all three scores have limitations in the application in juvenile systemic sclerosis patients. Furthermore, research on the concept of disease activity and suitable scores to measure disease activity in patients with juvenile systemic sclerosis is necessary in future.

OriginalsprogEngelsk
TidsskriftJournal of scleroderma and related disorders
Vol/bind8
Udgave nummer3
Sider (fra-til)183-191
Antal sider9
ISSN2397-1983
DOI
StatusUdgivet - okt. 2023

Fingeraftryk

Dyk ned i forskningsemnerne om 'Application and performance of disease activity indices proposed for patients with systemic sclerosis in an international cohort of patients with juvenile systemic sclerosis'. Sammen danner de et unikt fingeraftryk.

Citationsformater